Condition
KSHV Inflammatory Cytokine Syndrome (KICS)
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
6 treatments under study, led by Pacritinib
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT01419561Phase 2RecruitingPrimary
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT06052618Phase 2RecruitingPrimary
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Showing all 2 trials
Research Network
Common Treatments
- Pacritinib1
- Liposomal Doxorubicin1
- Standard Therapies1
- Rituximab1
- Valganiclovir1
Active Sponsors
- National Cancer Institute (NCI)2
Top Investigators
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Related Conditions
- Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease1
- Kshv1
- Hhv81